StockData
Merck & Co., Inc. logo

Merck & Co., Inc.

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$149.52+3.19 (+2.18%)

Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%

Merck Delstrigo (doravirine/lamivudine/tenofovir disoproxil by Quarter

Delstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate — HIV-1) — International sales ($M) ($M)

QuarterlyAnnual

Merck Delstrigo (doravirine/lamivudine/tenofovir disoproxil: $88M in Q2 2026, up 25.7% from a year earlier. That is the highest of the 14 quarters on record here.

Latest, Q2 2026
88
Period ended Jun 30, 2026
Change on a year earlier
+25.7%
70 in Q2 2025
History
14 quarters
Since Q1 2023
Sources
10
Documents cited below

Where the Q2 2026 figure comes from

“|| Delstrigo | 101 | 83 | 21 | 13 | 14 | -7 | 88 | 70 | 27”

Source: Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗

Reported in Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedDelstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate — HIV-1) — International sales ($M) ($M)Year on yearSource
Q2 2026Jun 30, 202688+25.7%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q1 2026Mar 31, 202665+25.0%Form 10-Q (filed 2026-05-04) ↗
Q4 2025Dec 31, 202565+18.2%Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q3 2025Sep 30, 202564+28.0%Form 8-K (tm2529620d1_ex99-1.htm, filed 2025-10-30) ↗
Q2 2025Jun 30, 202570+55.6%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q1 2025Mar 31, 202552+18.2%Form 8-K (tm2512885d1_ex99-1.htm, filed 2025-04-24) ↗
Q4 2024Dec 31, 202455+31.0%Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q3 2024Sep 30, 202450+25.0%Form 8-K (tm2529620d1_ex99-1.htm, filed 2025-10-30) ↗
Q2 2024Jun 30, 202445+21.6%Form 8-K (tm2521736d1_ex99-1.htm, filed 2025-07-29) ↗
Q1 2024Mar 31, 202444+33.3%Form 8-K (tm2512885d1_ex99-1.htm, filed 2025-04-24) ↗
Q4 2023Dec 31, 202342–Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
Q3 2023Sep 30, 202340–Form 8-K (tm2426878d1_ex99-1.htm, filed 2024-10-31) ↗
Q2 2023Jun 30, 202337–Form 8-K (tm2420272d1_ex99-1.htm, filed 2024-07-30) ↗
Q1 2023Mar 31, 202333–Form 8-K (tm2412490d1_ex99-1.htm, filed 2024-04-25) ↗

Breakdown

What makes up delstrigo (doravirine/lamivudine/tenofovir disoproxil

Cite this data

StockData. (2026). Merck Delstrigo (doravirine/lamivudine/tenofovir disoproxil ($M), quarterly Q1 2023–Q2 2026 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-delstrigo-intl

See every metric in the Merck KPI table. Data updated Oct 26, 2026.